ValuEngine Upgrades Catalent (CTLT) to “Buy”

ValuEngine upgraded shares of Catalent (NYSE:CTLT) from a hold rating to a buy rating in a research note issued to investors on Monday, April 15th, ValuEngine reports.

A number of other research firms also recently issued reports on CTLT. Zacks Investment Research downgraded shares of Catalent from a buy rating to a hold rating in a research note on Thursday, February 7th. First Analysis reiterated an outperform rating and set a $49.00 price target on shares of Catalent in a report on Tuesday, March 5th. Finally, TheStreet upgraded shares of Catalent from a c rating to a b- rating in a report on Wednesday, February 6th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $49.57.

NYSE:CTLT traded up $0.60 during midday trading on Monday, hitting $45.29. The company had a trading volume of 7,234 shares, compared to its average volume of 894,585. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08. Catalent has a 52-week low of $29.23 and a 52-week high of $47.04. The firm has a market capitalization of $6.67 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 2.41 and a beta of 1.70.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.07. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The business had revenue of $617.50 million during the quarter, compared to analyst estimates of $644.88 million. During the same period in the prior year, the business posted $0.41 earnings per share. The company’s revenue was down 1.7% on a year-over-year basis. On average, sell-side analysts forecast that Catalent will post 1.69 EPS for the current fiscal year.

In other news, insider Aristippos Gennadios sold 3,392 shares of the firm’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $42.18, for a total transaction of $143,074.56. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Lance Miyamoto sold 43,619 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $42.49, for a total transaction of $1,853,371.31. The disclosure for this sale can be found here. Insiders sold 54,326 shares of company stock worth $2,303,676 over the last quarter. Insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in Catalent by 29.5% during the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after buying an additional 1,819,020 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Catalent by 1.2% during the third quarter. Dimensional Fund Advisors LP now owns 1,270,970 shares of the company’s stock worth $57,891,000 after buying an additional 15,686 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in Catalent by 11.6% during the third quarter. Hsbc Holdings PLC now owns 24,198 shares of the company’s stock worth $1,101,000 after buying an additional 2,523 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Catalent during the third quarter worth $427,000. Finally, Deutsche Bank AG boosted its holdings in Catalent by 7.7% during the third quarter. Deutsche Bank AG now owns 426,540 shares of the company’s stock worth $19,425,000 after buying an additional 30,462 shares in the last quarter. Institutional investors own 96.85% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Read More: Purposes and Functions of the Federal Reserve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.